Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Capital Expenditures: 2017-2023

Historic Capital Expenditures for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Dec 2023 value amounting to -$1,000.

  • Rhythm Pharmaceuticals' Capital Expenditures changed negligibly% to -$1,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $46,000, marking a year-over-year decrease of 83.63%. This contributed to the annual value of $47,000 for FY2023, which is 83.27% down from last year.
  • Rhythm Pharmaceuticals' Capital Expenditures amounted to -$1,000 in Q4 2023, which was down 200.00% from $1,000 recorded in Q3 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Capital Expenditures peaked at $2.3 million during Q2 2019, and registered a low of -$1,000 during Q4 2022.
  • Moreover, its 3-year median value for Capital Expenditures was $60,000 (2022), whereas its average is $69,273.
  • Over the last 5 years, Rhythm Pharmaceuticals' Capital Expenditures had its largest YoY gain of 958.33% in 2022, and its largest YoY loss of 101.47% in 2022.
  • Quarterly analysis of 4 years shows Rhythm Pharmaceuticals' Capital Expenditures stood at $259,000 in 2019, then reached $68,000 in 2021, then tumbled by 101.47% to -$1,000 in 2022, then remained steady at -$1,000 in 2023.
  • Its last three reported values are -$1,000 in Q4 2023, $1,000 for Q3 2023, and $47,000 during Q1 2023.